Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Net revenue:
Total net revenue		$ 96,169	$ 102,562	$ 319,886	$ 285,353
Cost of revenue:
Total cost of revenue	[1]	61,385	63,020	202,951	169,577
Gross profit		34,784	39,542	116,935	115,776
Operating expenses:
Research and development	[2]	14,104	13,268	43,183	37,372
Selling and marketing		10,798	10,567	35,302	29,813
General and administrative		10,174	11,281	32,350	30,498
Total operating expenses		35,076	35,116	110,835	97,683
Income (loss) from operations		(292)	4,426	6,100	18,093
Income (loss) on equity method investment, net		1,946	(68)	774	1,021
Other expense, net		(2,293)	(4,027)	(7,451)	(12,981)
Income (loss) before provision for income taxes		(639)	331	(577)	6,133
Provision for income taxes		407	721	1,318	1,352
Net income (loss)		$ (1,046)	$ (390)	$ (1,895)	$ 4,781
Net income (loss) per share - basic		$ (0.01)	$ (0.00)	$ (0.02)	$ 0.05
Net income (loss) per share - diluted		$ (0.01)	$ (0.00)	$ (0.02)	$ 0.05
Weighted average common shares used in computing net income per share:
Basic		92,761	93,123	91,780	92,106
Diluted		92,761	93,123	91,780	93,422
Net income		$ (1,046)	$ (390)	$ (1,895)	$ 4,781
Foreign currency translation adjustment		(1,013)	(2,102)	(890)	1,199
Comprehensive income (loss)		(2,059)	(2,492)	(2,785)	5,980
Products
Net revenue:
Total net revenue	[3]	43,198	47,439	156,678	120,502
Cost of revenue:
Total cost of revenue		28,371	27,709	95,400	69,237
Services
Net revenue:
Total net revenue	[4]	52,971	55,123	163,208	164,851
Cost of revenue:
Total cost of revenue		$ 33,014	$ 35,311	$ 107,551	$ 100,340

[1] Includes cost of revenue from sales to the China joint venture, an equity method investment of $14,838 and $29,086 for the three and nine months ended March 31, 2022 and $2,387 and $7,088 for the three and nine months ended March 31, 2021, respectively.

[2] Includes chargeback to the China joint venture, an equity method investment related to research and development project of $549 and $1,543 for the three and nine months ended March 31, 2022 $0 and $430 for the three and nine months ended March 31, 2021.

[3] Includes sales to the China joint venture, an equity method investment of $17,442 and $32,177 for the three and nine months ended March 31, 2022 and $1,633 and $5,954 for the three and nine months ended March 31, 2021, respectively. See Note 14.

[4] Includes sales to the China joint venture, an equity method investment of $2,326 and $7,820 for the three and nine months ended March 31, 2022 and $4,934 and $10,197 for the three and nine months ended March 31, 2021, respectively. See Note 14.